Clinical Trial

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-11; most recent amendment 2025-12-11.
Status change: Not Yet Recruiting → Recruiting 2025-02-07
Trial Details
NCT Number NCT06686576
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Colon Cancer
Enrollment 363 participants
Start Date 2024-12-12
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-18